Skip to main content
. 2020 Dec 8;11:6298. doi: 10.1038/s41467-020-20140-0

Fig. 8. Enhanced therapeutic benefits in OC by targeting tumor-derived Ubr5.

Fig. 8

a Dose response curves of ID8 treated with cisplatin for 72 h (n = 5 biologically independent samples per group). The averages of three independent experiments were plotted, data are presented as mean ± SD, P < 0.0001, one-way ANOVA test. b Western blot analysis of cleaved-PARP levels after 24 h of cisplatin (Cis) treatment in ID8 cells. c, d UBR5 overexpression abrogated the therapeutic effect of cisplatin treatment. ID8 bearing mice were treated with cisplatin at 2 weeks after tumor implantation once a week for 3 weeks (n = 5 mice per group). Mouse mortality (c) and body weight (d) were monitored. Data are presented as mean ± SD, unpaired two-sided Student’s t-test. e Anti-PD-1 treatment enhanced the survival of ID8/Ubr5−/− bearing mice, but not ID8/GFP bearing mice. Mice were treated with anti-PD-1 at indicated times post tumor implantation, and survival rates were quantified (n = 10 mice per group). Data shown is pooled from two independent experiments. f 4H1128z cells administration resulted in long-term survival of mice harboring ID8/Ubr5−/−. Mice were treated with CAR-T cells 2 weeks after tumor implantation, and survival rates were quantified (n = 10 mice per group). In all cases, data are representative of at least two independent experiments. P values shown in c, e, and f were calculated by log rank test. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file.